These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35207711)

  • 1. Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease.
    Georgianos PI; Vaios V; Roumeliotis S; Leivaditis K; Eleftheriadis T; Liakopoulos V
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors.
    Georgianos PI; Vaios V; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
    Curr Pharm Des; 2021; 27(8):1043-1050. PubMed ID: 33463454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes - a minireview.
    Wieczorek-Surdacka E; Surdacki A; Świerszcz J; Chyrchel B
    Folia Med Cracov; 2020; 60(4):97-101. PubMed ID: 33821854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial.
    Antlanger M; Domenig O; Kaltenecker CC; Kovarik JJ; Rathkolb V; Müller MM; Schwaiger E; Hecking M; Poglitsch M; Säemann MD; Kopecky C
    Diabetes Obes Metab; 2022 May; 24(5):816-826. PubMed ID: 34984822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
    Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
    Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review.
    González-González JG; Díaz González-Colmenero A; Millán-Alanís JM; Lytvyn L; Solis RC; Mustafa RA; Palmer SC; Li S; Hao Q; Alvarez-Villalobos NA; Vandvik PO; Rodríguez-Gutiérrez R
    BMJ Open; 2021 Jul; 11(7):e049130. PubMed ID: 34244276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.
    von Scholten BJ; Kreiner FF; Rasmussen S; Rossing P; Idorn T
    Ther Adv Endocrinol Metab; 2022; 13():20420188221112490. PubMed ID: 35874312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
    Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S
    Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
    Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis.
    Kawai Y; Uneda K; Yamada T; Kinguchi S; Kobayashi K; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
    Diabetes Res Clin Pract; 2022 Jan; 183():109146. PubMed ID: 34780865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes.
    Shami D; Sousou JM; Batarseh E; Alazrai L
    Cureus; 2023 Jan; 15(1):e33484. PubMed ID: 36751181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
    Sarafidis P; Ferro CJ; Morales E; Ortiz A; Malyszko J; Hojs R; Khazim K; Ekart R; Valdivielso J; Fouque D; London GM; Massy Z; Ruggenenti P; Porrini E; Wiecek A; Zoccali C; Mallamaci F; Hornum M
    Nephrol Dial Transplant; 2019 Feb; 34(2):208-230. PubMed ID: 30753708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.
    Puglisi S; Rossini A; Poli R; Dughera F; Pia A; Terzolo M; Reimondo G
    Front Endocrinol (Lausanne); 2021; 12():738848. PubMed ID: 34745006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
    Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
    Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The residual cardiorenal risk in type 2 diabetes.
    Giugliano D; Maiorino MI; Bellastella G; Esposito K
    Cardiovasc Diabetol; 2021 Feb; 20(1):36. PubMed ID: 33546683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.